Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-17
2007-04-17
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S509000
Reexamination Certificate
active
10547228
ABSTRACT:
The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
REFERENCES:
Goadsby et al., “Vasoactive Peptide Release in the Extracerebral Circulation of Humans During Migraine Headache”, Annals of Neurology, vol. 28, No. 2, pp. 183-187 (1990).
Bell Ian M.
Graham Samuel L.
Stump Craig A.
Williams Theresa M.
Kifle Bruck
Merck & Co. , Inc.
Rose David L.
Rubin David
LandOfFree
Benodiazepine spirohydantoin CGRP receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benodiazepine spirohydantoin CGRP receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benodiazepine spirohydantoin CGRP receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3805221